171 related articles for article (PubMed ID: 10194124)
1. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells.
Drexler HG; Meyer C; Quentmeier H
Leuk Lymphoma; 1999 Mar; 33(1-2):83-91. PubMed ID: 10194124
[TBL] [Abstract][Full Text] [Related]
2. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
3. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.
Lisovsky M; Estrov Z; Zhang X; Consoli U; Sanchez-Williams G; Snell V; Munker R; Goodacre A; Savchenko V; Andreeff M
Blood; 1996 Nov; 88(10):3987-97. PubMed ID: 8916965
[TBL] [Abstract][Full Text] [Related]
4. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.
Dehmel U; Zaborski M; Meierhoff G; Rosnet O; Birnbaum D; Ludwig WD; Quentmeier H; Drexler HG
Leukemia; 1996 Feb; 10(2):261-70. PubMed ID: 8637235
[TBL] [Abstract][Full Text] [Related]
5. FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines.
Meyer C; Drexler HG
Leuk Lymphoma; 1999 Feb; 32(5-6):577-81. PubMed ID: 10048431
[TBL] [Abstract][Full Text] [Related]
6. Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors.
Piacibello W; Fubini L; Sanavio F; Brizzi MF; Severino A; Garetto L; Stacchini A; Pegoraro L; Aglietta M
Blood; 1995 Dec; 86(11):4105-14. PubMed ID: 7492767
[TBL] [Abstract][Full Text] [Related]
7. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta.
Veiby OP; Jacobsen FW; Cui L; Lyman SD; Jacobsen SE
J Immunol; 1996 Oct; 157(7):2953-60. PubMed ID: 8816402
[TBL] [Abstract][Full Text] [Related]
8. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.
Meierhoff G; Dehmel U; Gruss HJ; Rosnet O; Birnbaum D; Quentmeier H; Dirks W; Drexler HG
Leukemia; 1995 Aug; 9(8):1368-72. PubMed ID: 7643626
[TBL] [Abstract][Full Text] [Related]
9. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells.
Quentmeier H; Zaborski M; Graf G; Ludwig WD; Drexler HG
Leukemia; 1996 Feb; 10(2):297-310. PubMed ID: 8637239
[TBL] [Abstract][Full Text] [Related]
10. Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines.
Dehmel U; Quentmeier H; Drexler HG
Leukemia; 1996 Feb; 10(2):271-8. PubMed ID: 8637236
[TBL] [Abstract][Full Text] [Related]
11. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts.
Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W
Leukemia; 1996 Oct; 10(10):1584-91. PubMed ID: 8847893
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells.
Drexler HG; Quentmeier H
Leukemia; 1996 Sep; 10(9):1405-21. PubMed ID: 8751457
[TBL] [Abstract][Full Text] [Related]
13. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
14. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
15. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression.
Zhang D; Guo Y; Zhao Y; Yu L; Chang Z; Pei H; Huang J; Chen C; Xue H; Xu X; Pan Y; Li N; Zhu C; Zhao ZJ; Yu J; Chen Y
Microb Cell Fact; 2021 Mar; 20(1):67. PubMed ID: 33691697
[TBL] [Abstract][Full Text] [Related]
16. Effects of Flt3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells.
Eder M; Hemmati P; Kalina U; Ottman OG; Hoelzer D; Lyman SD; Ganser A
Exp Hematol; 1996 Feb; 24(2):371-7. PubMed ID: 8641368
[TBL] [Abstract][Full Text] [Related]
17. Differential response to stem cell factor and Flt3 ligand by the FAB subtype in acute myeloid leukemia clonogenic cells.
Murohashi I; Yoshida K; Kishimoto K; Takahashi T; Wakao D; Jinnai I; Yagasaki F; Kawai N; Suzuki T; Matsuda A; Hirashima K; Bessho M
J Interferon Cytokine Res; 2002 Mar; 22(3):335-41. PubMed ID: 12034041
[TBL] [Abstract][Full Text] [Related]
18. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
19. Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children.
McKenna HJ; Smith FO; Brasel K; Hirschstein D; Bernstein ID; Williams DE; Lyman SD
Exp Hematol; 1996 Feb; 24(2):378-85. PubMed ID: 8641369
[TBL] [Abstract][Full Text] [Related]
20. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.
Zheng R; Klang K; Gorin NC; Small D
Leuk Res; 2004 Feb; 28(2):121-6. PubMed ID: 14654075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
